Tomonori Yamanishi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8158183/publications.pdf

Version: 2024-02-01

		126907	155660
110	3,336	33	55
papers	citations	h-index	g-index
111	111	111	2401
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Symptom assessment tool for overactive bladder syndrome—overactive bladder symptom score. Urology, 2006, 68, 318-323.	1.0	582
2	Combination of a cholinergic drug and an alpha-blocker is more effective than monotherapy for the treatment of voiding difficulty in patients with underactive detrusor. International Journal of Urology, 2004, 11, 88-96.	1.0	110
3	Randomized, double-blind study of electrical stimulation for urinary incontinence due to detrusor overactivity. Urology, 2000, 55, 353-357.	1.0	109
4	PELVIC FLOOR ELECTRICAL STIMULATION IN THE TREATMENT OF STRESS INCONTINENCE: AN INVESTIGATIONAL STUDY AND A PLACEBO CONTROLLED DOUBLE-BLIND TRIAL. Journal of Urology, 1997, 158, 2127-2131.	0.4	103
5	Assessment of Overactive Bladder Symptoms: Comparison of 3-Day Bladder Diary and the Overactive Bladder Symptoms Score. Urology, 2011, 77, 60-64.	1.0	97
6	Incomplete emptying and urinary retention in multiple-system atrophy: When does it occur and how do we manage it?. Movement Disorders, 2006, 21, 816-823.	3.9	91
7	Clinical guidelines for male lower urinary tract symptoms and benign prostatic hyperplasia. International Journal of Urology, 2017, 24, 716-729.	1.0	90
8	Overactive bladder in diabetes: A peripheral or central mechanism?. Neurourology and Urodynamics, 2007, 26, 807-813.	1.5	88
9	Comparative study of the effects of magnetic versus electrical stimulation on inhibition of detrusor overactivity. Urology, 2000, 56, 777-781.	1.0	78
10	The role of M ₂ â€muscarinic receptors in mediating contraction of the pig urinary bladder <i>in vitro</i> . British Journal of Pharmacology, 2000, 131, 1482-1488.	5.4	71
11	Randomized, Placebo Controlled Study of Electrical Stimulation With Pelvic Floor Muscle Training for Severe Urinary Incontinence After Radical Prostatectomy. Journal of Urology, 2010, 184, 2007-2012.	0.4	71
12	Defining overactive bladder as hypersensitivity. Neurourology and Urodynamics, 2007, 26, 904-907.	1.5	69
13	Outline of JUA clinical guidelines for benign prostatic hyperplasia. International Journal of Urology, 2011, 18, 741-756.	1.0	66
14	EFFECT OF FUNCTIONAL CONTINUOUS MAGNETIC STIMULATION FOR URINARY INCONTINENCE. Journal of Urology, 2000, 163, 456-459.	0.4	65
15	Sphincter EMG as a diagnostic tool in autonomic disorders. Clinical Autonomic Research, 2009, 19, 20-31.	2.5	65
16	Are alpha-blockers involved in lower urinary tract dysfunction in multiple system atrophy?. Journal of the Autonomic Nervous System, 2000, 79, 191-195.	1.9	58
17	BIOFEEDBACK TRAINING FOR DETRUSOR OVERACTIVITY IN CHILDREN. Journal of Urology, 2000, 164, 1686-1690.	0.4	55
18	Urinary retention due to herpes virus infections. Neurourology and Urodynamics, 1998, 17, 613-619.	1.5	51

#	Article	IF	CITATIONS
19	The role of \hat{l}^23 -adrenoceptors in mediating relaxation of porcine detrusor muscle. British Journal of Pharmacology, 2002, 135, 129-134.	5.4	50
20	Influence of Body Position on Defecation in Humans. LUTS: Lower Urinary Tract Symptoms, 2010, 2, 16-21.	1.3	50
21	Urological dysfunction in synucleinopathies: epidemiology, pathophysiology and management. Clinical Autonomic Research, 2018, 28, 83-101.	2.5	46
22	Clinical guideline for male lower urinary tract symptoms. International Journal of Urology, 2009, 16, 775-790.	1.0	44
23	Urodynamic effects of silodosin, a new α _{1A} â€adrenoceptor selective antagonist, for the treatment of benign prostatic hyperplasia. Neurourology and Urodynamics, 2010, 29, 558-562.	1.5	43
24	THE ROLE OF M2 MUSCARINIC RECEPTOR SUBTYPES IN MEDIATING CONTRACTION OF THE PIG BLADDER BASE AFTER CYCLIC ADENOSINE MONOPHOSPHATE ELEVATION AND/OR SELECTIVE M3 INACTIVATION. Journal of Urology, 2002, 167, 397-401.	0.4	42
25	Effect of functional continuous magnetic stimulation on urethral closure in healthy volunteers. Urology, 1999, 54, 652-655.	1.0	41
26	Neuromodulation for the Treatment of Lower Urinary Tract Symptoms. LUTS: Lower Urinary Tract Symptoms, 2015, 7, 121-132.	1.3	41
27	The influence of afferent inputs from skin and viscera on the activity of the bladder and the skeletal muscle surrounding the urethra in the rat. Neuroscience Research, 1995, 23, 195-205.	1.9	39
28	Neuromodulation for the treatment of urinary incontinence. International Journal of Urology, 2008, 15, 665-672.	1.0	38
29	Randomized, double-blind, sham-controlled evaluation of the effect of functional continuous magnetic stimulation in patients with urgency incontinence. Neurourology and Urodynamics, 2007, 26, 767-772.	1.5	37
30	Clinical Guideline for Female Lower Urinary Tract Symptoms. LUTS: Lower Urinary Tract Symptoms, 2016, 8, 5-29.	1.3	37
31	Multicenter, randomized, shamâ€controlled study on the efficacy of magnetic stimulation for women with urgency urinary incontinence. International Journal of Urology, 2014, 21, 395-400.	1.0	36
32	Effect of naftopidil on urethral obstruction in benign prostatic hyperplasia: Assessment by urodynamic studies. Prostate, 1994, 25, 46-52.	2.3	35
33	The Effect of Urapidil on Neurogenic Bladder: A Placebo Controlled Double-Blind Study. Journal of Urology, 1996, 156, 1125-1130.	0.4	34
34	Variation in urinary flow according to voiding position in normal males. Neurourology and Urodynamics, 1999, 18, 553-557.	1.5	34
35	Role of ?-adrenoceptor subtypes in mediating relaxation of the pig bladder trigonal muscle in vitro. Neurourology and Urodynamics, 2003, 22, 338-342.	1.5	33
36	Single-blind, randomized controlled study of the clinical and urodynamic effects of an alpha-blocker (naftopidil) and phytotherapy (eviprostat) in the treatment of benign prostatic hyperplasia. International Journal of Urology, 2004, 11, 501-509.	1.0	33

#	Article	IF	Citations
37	Detrusor Overactivity and Penile Erection in Patients with Lower Lumbar Spine Lesions. European Urology, 1998, 34, 360-364.	1.9	31
38	The Role of M2 Muscarinic Receptor Subtypes Mediating Contraction of the Circular and Longitudinal Smooth Muscle of the Pig Proximal Urethra. Journal of Urology, 2002, 168, 308-314.	0.4	30
39	Effects of 138–355, a β3-adrenoceptor selective agonist, on relaxation of the human detrusor muscle in vitro. Neurourology and Urodynamics, 2006, 25, 815-819.	1.5	30
40	A Multicenter Placebo-Controlled, Double-Blind Trial of Urapidil, an α-Blocker, on Neurogenic Bladder Dysfunction. European Urology, 1999, 35, 45-51.	1.9	28
41	Evaluation of functional bladder capacity in Japanese children. International Journal of Urology, 1999, 6, 226-228.	1.0	27
42	Clinical guidelines for the diagnosis and treatment of lower urinary tract dysfunction in patients with spinal cord injury. International Journal of Urology, 2020, 27, 276-288.	1.0	25
43	Effects of magnetic stimulation on urodynamic stress incontinence refractory to pelvic floor muscle training in a randomized shamâ€controlled study. LUTS: Lower Urinary Tract Symptoms, 2019, 11, 61-65.	1.3	24
44	Efficacy and safety of intravesical instillation of KRPâ€116D (50% dimethyl sulfoxide solution) for interstitial cystitis/bladder pain syndrome in Japanese patients: A multicenter, randomized, doubleâ€blind, placeboâ€controlled, clinical study. International Journal of Urology, 2021, 28, 545-553.	1.0	24
45	Efficacy of extendedâ€release tolterodine for the treatment of neurogenic detrusor overactivity and/or lowâ€compliance bladder. International Journal of Urology, 2010, 17, 931-936.	1.0	23
46	OnabotulinumtoxinA (botulinum toxin typeÂA) for the treatment of Japanese patients with overactive bladder and urinary incontinence: Results of singleâ€dose treatment from a phaseÂllI, randomized, doubleâ€blind, placeboâ€controlled trial (interim analysis). International Journal of Urology, 2020, 27, 227-234.	1.0	22
47	A randomized controlled study of the efficacy of tadalafil monotherapy versus combination of tadalafil and mirabegron for the treatment of persistent overactive bladder symptoms in men presenting with lower urinary tract symptoms (CONTACT Study). Neurourology and Urodynamics, 2020, 39, 804-812.	1.5	22
48	Role of urodynamic studies in the diagnosis and treatment of lower urinary tract symptoms. Urological Science, 2011, 22, 120-128.	0.6	18
49	Clinical Guidelines for Female Lower Urinary Tract Symptoms (second edition). International Journal of Urology, 2021, 28, 474-492.	1.0	18
50	Increased interferon alpha receptor 2 mRNA levels is associated with renal cell carcinoma metastasis. BMC Cancer, 2007, 7, 159.	2.6	17
51	Urodynamic evaluation of surgical outcome in patients with urinary retention due to central lumbar disc prolapse. Neurourology and Urodynamics, 2003, 22, 670-675.	1.5	16
52	The Functional Role of \hat{l}^2 -Adrenoceptor Subtypes in Mediating Relaxation of Pig Urethral Smooth Muscle. Journal of Urology, 2003, 170, 2508-2511.	0.4	16
53	Expression of RhoA mRNA and activated RhoA in urothelium and smooth muscle, and effects of a rhoâ€kinase inhibitor on contraction of the porcine urinary bladder. Neurourology and Urodynamics, 2009, 28, 521-528.	1.5	16
54	Molecular pathogenesis of interstitial cystitis based on microRNA expression signature: miR-320 family-regulated molecular pathways and targets. Journal of Human Genetics, 2018, 63, 543-554.	2.3	16

#	Article	IF	CITATIONS
55	Induction of urethral closure and inhibition of bladder contraction by continuous magnetic stimulation. Neurourology and Urodynamics, 1999, 18, 505-510.	1.5	15
56	Efficacy and safety of combination therapy with tamsulosin, dutasteride and imidafenacin for the management of overactive bladder symptoms associated with benign prostatic hyperplasia: A multicenter, randomized, openâ€label, controlled trial (<scp>DI</scp> recT Study). International Journal of Urology, 2017, 24, 525-531.	1.0	15
57	Identification of \hat{l}^2 -Adrenoceptor Subtypes in Lower Urinary Tract of the Female Pig. Journal of Urology, 2002, 168, 2706-2710.	0.4	14
58	The role of muscarinic receptor subtypes on carbachol-induced contraction of normal human detrusor and overactive detrusor associated with benign prostatic hyperplasia. Journal of Pharmacological Sciences, 2015, 128, 65-70.	2.5	14
59	Mirabegron or tolterodine for the treatment of overactive bladder in Japan: Which drug is more costâ€effective as the firstâ€line treatment?. International Journal of Urology, 2018, 25, 863-870.	1.0	13
60	The role of M2 muscarinic receptor subtypes in mediating contraction of the pig bladder base after cyclic adenosine monophosphate elevation and/or selective M3 inactivation. Journal of Urology, 2002, 167, 397-401.	0.4	13
61	Urinary dysfunction in Brown-Séquard syndrome. Neurourology and Urodynamics, 2001, 20, 661-667.	1.5	12
62	Continuous urinary incontinence presenting as the initial symptoms demonstrating acontractile detrusor and intrinsic sphincter deficiency in multiple system atrophy. International Journal of Urology, 2007, 14, 972-974.	1.0	12
63	Nocturia Quality-of-Life questionnaire is a useful tool to predict nocturia and a risk of falling in Japanese outpatients: A cross-sectional survey. International Journal of Urology, 2014, 21, 289-293.	1.0	12
64	Sixâ€year follow up of silodosin monotherapy for the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: What are the factors for continuation or withdrawal?. International Journal of Urology, 2015, 22, 1143-1148.	1.0	11
65	Urethral obstruction in patients with nighttime wetting: Urodynamic evaluation and outcome of surgical incision. Neurourology and Urodynamics, 2000, 19, 241-248.	1.5	10
66	Design of a single-arm clinical trial of regenerative therapy by periurethral injection of adipose-derived regenerative cells for male stress urinary incontinence in Japan: the ADRESU study protocol. BMC Urology, 2017, 17, 89.	1.4	10
67	Regenerative treatment for male stress urinary incontinence by periurethral injection of adiposeâ€derived regenerative cells: Outcome of the ADRESU study. International Journal of Urology, 2020, 27, 859-865.	1.0	10
68	Transurethral Holmium: YAG Laser Prostatectomy Using a Side– Firing Fiber for Bladder Outlet Obstruction due to Benign Prostatic Enlargement: Urodynamic Evaluation of Surgical Outcome. European Urology, 2001, 39, 544-550.	1.9	9
69	Onceâ€daily oxybutynin patch improves nocturia and sleep quality in Japanese patients with overactive bladder: Postâ€hoc analysis of a phase III randomized clinical trial. International Journal of Urology, 2015, 22, 684-688.	1.0	9
70	URINE FLOW DYNAMICS THROUGH THE URETHRA IN PATIENTS WITH BLADDER OUTLET OBSTRUCTION. Journal of Mechanics in Medicine and Biology, 2014, 14, 1450052.	0.7	8
71	Expression profile of urothelial transcription factors in bladder biopsies with interstitial cystitis. International Journal of Urology, 2017, 24, 632-638.	1.0	8
72	Autologous and heterotopic transplantation of adipose stromal vascular fraction ameliorates stress urinary incontinence in rats with simulated childbirth trauma. Regenerative Therapy, 2018, 8, 9-14.	3.0	8

#	Article	IF	CITATIONS
73	Micturitional disturbance in a patient with neurosarcoidosis. Neurourology and Urodynamics, 2000, 19, 273-277.	1.5	7
74	Effects of fasudil, a Rhoâ€kinase inhibitor, on contraction of pig bladder tissues with or without urothelium. International Journal of Urology, 2009, 16, 959-966.	1.0	7
75	Effects of Silodosin on Lower Urinary Tract Symptoms in Patients with Benign Prostatic Hyperplasia: Evaluation by Frequency/Volume Chart. LUTS: Lower Urinary Tract Symptoms, 2010, 2, 31-36.	1.3	7
76	Do Sacral/Peripheral Lesions Contribute to Detrusor‧phincter Dyssynergia?. LUTS: Lower Urinary Tract Symptoms, 2012, 4, 126-129.	1.3	6
77	Therapeutic effect of propiverine hydrochloride on mixedâ€type urinary incontinence in women: The Female Urgency and Stress Urinary Incontinence Study of Propiverine Hydrochloride trial. International Journal of Urology, 2018, 25, 486-491.	1.0	6
78	Long-Term Efficacy of Tamsulosin in the Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia in Real-Life Practice. UroToday International Journal, 2009, 02, .	0.1	6
79	JUA clinical guidelines for benign prostatic hyperplasia. International Journal of Urology, 2011, 18, e1.	1.0	5
80	Nocturia Potentially Influences Maintenance of Sexual Function in Elderly Men with Benign Prostatic Hyperplasia. LUTS: Lower Urinary Tract Symptoms, 2013, 5, 75-81.	1.3	5
81	A 52â€week multicenter randomized controlled study of the efficacy and safety of addâ€on dutasteride and imidafenacin to tamsulosin in patients with benign prostatic hyperplasia with remaining overactive bladder symptoms (DlrecT study). LUTS: Lower Urinary Tract Symptoms, 2019, 11, 115-121.	1.3	5
82	Comparison of the clinical effect of dutasteride therapy for benign prostatic hyperplasia when initiated at different time points: A multicentre, observational, retrospective chart review study. International Journal of Clinical Practice, 2019, 73, e13418.	1.7	4
83	Urodynamic efficacy of fesoterodine for the treatment of neurogenic detrusor overactivity and/or low compliance bladder. International Journal of Urology, 2020, 27, 899-904.	1.0	4
84	Identification of beta-adrenoceptor subtypes in lower urinary tract of the female pig. Journal of Urology, 2002, 168, 2706-10.	0.4	4
85	Ambulatory Urodynamics in Asymptomatic, Young, Healthy Male Volunteers. LUTS: Lower Urinary Tract Symptoms, 2009, 1, 29-34.	1.3	3
86	Pulsed magnetic stimulation with a highâ€frequency continuous magnetic stimulator (SMNâ€X) does not exert an adverse effect on genital organs and the estrous cycle in female lar:Wistarâ€Imamichi rats. Neurourology and Urodynamics, 2011, 30, 1675-1680.	1.5	3
87	Efficacy and safety of onabotulinumtoxinA in patients with overactive bladder: subgroup analyses by sex and by serum prostate-specific antigen levels in men from a randomized controlled trial. International Urology and Nephrology, 2021, 53, 2243-2250.	1.4	3
88	THE ROLE OF M2 MUSCARINIC RECEPTOR SUBTYPES IN MEDIATING CONTRACTION OF THE PIG BLADDER BASE AFTER CYCLIC ADENOSINE MONOPHOSPHATE ELEVATION AND/OR SELECTIVE M3 INACTIVATION. Journal of Urology, 2002, , 397-401.	0.4	3
89	The Role of M2 Muscarinic Receptor Subtypes Mediating Contraction of the Circular and Longitudinal Smooth Muscle of the Pig Proximal Urethra. Journal of Urology, 2002, , 308-314.	0.4	3
90	Randomized, Singleâ€Blind, Parallel Study of the Effectiveness and Safety of Solifenacin versus Propiverine in the Treatment of Overactive Bladder. LUTS: Lower Urinary Tract Symptoms, 2013, 5, 11-16.	1.3	2

#	Article	IF	CITATIONS
91	Highâ€Frequency Continuous Pulsed Magnetic Stimulation Does Not Adversely Affect Development on Whole Body Organs in Female Sprague–Dawley Rats. LUTS: Lower Urinary Tract Symptoms, 2017, 9, 102-106.	1.3	2
92	Bladder sensation evaluation of a carrageenanâ€induced chronic prostatitis model using a direct measurement of the bladder mechanosensitive singleâ€unit afferent nerve activity. Neurourology and Urodynamics, 2020, 39, 2111-2119.	1.5	2
93	The Effect of Urapidil on Neurogenic Bladder. Journal of Urology, 1996, , 1125-1130.	0.4	2
94	Management of benign prostatic hyperplasia with silodosin. Open Access Journal of Urology, $0, 1$.	0.3	2
95	Management of benign prostatic hyperplasia with silodosin. Research and Reports in Urology, 2009, Volume 1, 1-7.	1.0	2
96	Supervised machine learning algorithm identified KRT20, BATF and TP63 as biologically relevant biomarkers for bladder biopsy specimens from interstitial cystitis/bladder pain syndrome patients. International Journal of Urology, 2022, , .	1.0	2
97	Psychogenic Urinary Dysfunction in Children and Adults. Current Bladder Dysfunction Reports, 2012, 7, 242-246.	0.5	1
98	The Mechanism of and a Novel Treatment for Neurogenic Lower Urinary Tract Dysfunction (Neurogenic Bladder). Spinal Surgery, 2013, 27, 4-12.	0.0	1
99	Extravasation of Urine Associated with Bilateral Complete Ureteral Duplication, Vesicoureteral Reflux and Benign Prostatic Hyperplasia. Urology Case Reports, 2017, 11, 47-49.	0.3	1
100	Which β-Adrenoceptor Subtypes are Important in the Treatment of Overactive Bladder?. Current Drug Therapy, 2007, 2, 79-84.	0.3	0
101	Editorial Comment to Effectiveness and safety of silodosin in the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia: A European phase IV clinical study (SiRE study). International Journal of Urology, 2016, 23, 580-580.	1.0	0
102	Editorial Comment from Dr Yamanishi to Longâ€ŧerm safety and efficacy of the novel β⟨sub⟩3⟨ sub⟩â€∎drenoreceptor agonist vibegron in Japanese patients with overactive bladder: A phase III prospective study. International Journal of Urology, 2018, 25, 676-676.	1.0	0
103	Editorial commentary on "Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo― Translational Andrology and Urology, 2020, 9, 1009-1012.	1.4	0
104	Back Cover Image, Volume 39, Number 2, February 2020. Neurourology and Urodynamics, 2020, 39, iii.	1.5	0
105	Triple Therapy with Tamsulosin, Dutasteride, and Imidafenacin for Benign Prostatic Hyperplasia in Patients with Overactive Bladder Symptoms Refractory to Tamsulosin: Subgroup Analyses of the DirecT Study. Urologia Internationalis, 2021, 105, 817-825.	1.3	O
106	Editorial Comment to Efficacy of mirabegron, a β ₃ â€adrenoreceptor agonist, in Japanese women with overactive bladder and either urgency urinary incontinence or mixed urinary incontinence: Postâ€hoc analysis of pooled data from two randomized, placeboâ€controlled, doubleâ€blind studies. International Journal of Urology, 2022, 29, 15-16.	1.0	0
107	CS1-1 Physical therapy and neuromodulation(Comprehensive Study 1「Treatment Strategy for Obstinate) Tj	ETOq1 1 (0:1).784314 rg8
108	A Novel Drug Therapy and Electrical/Magnetic Stimulation for the Treatment of Lower Urinary Tract Dysfunction. Spinal Surgery, 2014, 28, 11-16.	0.0	0

#	Article	IF	CITATIONS
109	Editorial Comment. Journal of Urology, 2020, 203, 191-191.	0.4	O
110	Influence of background characteristics in responders of regenerative therapy by periurethral injection of adiposeâ€derived regenerative cells for male stress urinary incontinence. LUTS: Lower Urinary Tract Symptoms, 2022, , .	1.3	0